Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …